5-Amino-1MQ: How It Works, Metabolic Benefits and Oral vs. Injectable Research
5-Amino-1MQ is a small-molecule compound studied for its effects on fat metabolism, body composition and glucose regulation. It targets nicotinamide N-methyltransferase—NNMT, an enzyme that connects nicotinamide metabolism with the body’s methylation pathways.
Its defining feature is this enzyme-based mechanism. Published experiments have investigated changes in fat tissue, cellular NAD+, insulin sensitivity and liver fat. Understanding those findings starts with understanding what NNMT does.
What is 5-Amino-1MQ?
The name stands for 5-amino-1-methylquinolinium. Although frequently discussed alongside peptides, it is chemically a small molecule. Peptides consist of linked amino acids; 5-Amino-1MQ has a different molecular structure.
Researchers use it to investigate what happens when NNMT activity is reduced. Its effects have been characterized in cultured cells and animal models, including mice with diet-induced obesity. [1]
How its mechanism works
NNMT transfers a methyl group from S-adenosylmethionine, or SAM, to nicotinamide, producing 1-methylnicotinamide.
Nicotinamide also participates in the salvage pathway that regenerates NAD+, a coenzyme involved in cellular energy reactions. SAM supplies methyl groups for numerous biochemical processes.
In cultured fat cells, NNMT inhibition increased intracellular NAD+ and SAM while reducing lipogenesis—the production of new fat. This establishes a biochemical connection between NNMT inhibition and changes in fat-cell metabolism.
Calling 5-Amino-1MQ simply an “NAD+ booster” misses part of this mechanism: its direct target is NNMT, with downstream effects on several connected pathways. [1]
For a closer look at cellular energy and nicotinamide recycling, read our guide to NAD+ metabolism, mitochondria and DNA repair.
Fat loss and body composition
An early study in diet-induced obese mice found that treatment reduced body weight, white adipose tissue mass and fat-cell size. Total food intake did not decrease, and circulating total cholesterol fell.
The unchanged food intake matters: the observed weight changes were not explained by the animals simply eating less. That finding helped establish interest in NNMT as a target for obesity research. It does not establish a specific amount of weight loss in people. [1]
What happened when treatment was combined with diet?
A 2021 study examined NNMT inhibition alongside a switch from an obesity-promoting diet to a lean diet. Compared with the dietary change alone, the combination:
Accelerated body-weight and fat loss.
Increased the proportion of body weight represented by lean mass.
Reduced liver and white-fat-tissue weights.
Reduced liver fat accumulation.
Brought several body-composition and liver-fat measures toward those of lean control mice.
An increased lean-mass percentage is different from new muscle growth: reducing fat can increase the proportion of lean tissue without adding muscle.
The researchers also identified changes in fat-tissue metabolites associated with energy metabolism. These findings connected the visible changes in body composition with measurable biochemical changes. [2]
Glucose regulation and insulin sensitivity
In a 2024 study, researchers administered 5-Amino-1MQ to obese mice over 28 days. Treatment improved glucose tolerance and insulin sensitivity and reduced elevated insulin levels.
These measurements describe related but distinct processes. Glucose tolerance concerns how effectively the body handles a glucose load. Insulin sensitivity concerns how effectively tissues respond to insulin.
The study also found reduced weight and fat-mass gain without a change in lean mass. [3]
Liver-fat findings
The same study documented less liver-fat accumulation, lower liver triglycerides and reduced inflammatory-cell infiltration. Several circulating markers associated with liver injury and metabolic dysfunction also improved.
This broadens the research interest beyond body weight alone: investigators are examining the metabolic complications that accompany excess fat accumulation. These remain animal-study findings, rather than established treatment outcomes in people. [3]
Oral versus subcutaneous administration
Oral administration requires gastrointestinal absorption before the compound reaches systemic circulation. Subcutaneous administration delivers it into tissue beneath the skin, where it is absorbed into circulation.
Researchers have measured 5-Amino-1MQ exposure after oral, intravenous and subcutaneous administration in mice. Subcutaneous dosing produced systemic exposure and distribution to metabolically active tissues, including fat, muscle and liver.
These measurements answer questions about exposure and distribution in the experimental animals. They do not supply a validated human conversion between an oral dose and an injected dose. [3]
Dosing and the proposed 6–8-week cycle
The proposed amounts—50–150 mg orally daily or 5–50 mg subcutaneously daily for 6–8 weeks—are not validated by the human clinical research identified for this article. They should not be described as scientifically established dosing.
Related Kelden resources
Explore more mechanism-focused articles in the Kelden Research Hub. For help interpreting analytical documentation, read how to read a certificate of analysis and review our published lab reports. General ordering and research-use information is available in our FAQ.